Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

What Is Pfizer (NYSE:PFE) Expected to Show in Its November 3 Third Quarter Report?

● Consensus is about 73 cents adjusted EPS on revenue near $15.9 billion, per outside estimates.

Nitish Kishor | 28 October 2026

Inside the Tilray Brands (NASDAQ:TLRY) Quarter: BrewDog Lifts Beverages While Cannabis Falls

● Beverage revenue rose about 82% to roughly $101.5 million on the BrewDog acquisition.

Nitish Kishor | 28 October 2026

Why Is UnitedHealth Group (NYSE:UNH) Back in Focus After Its Third Quarter Beat and Higher Guidance?

● Medical care ratio improved to 88.4% from 89.9%, aided by roughly $610 million reserve benefit.

Nitish Kishor | 28 October 2026

Vericel (NASDAQ:VCEL) Sets November 5 Date for Third-Quarter Results After a Guidance Raise

● Second-quarter net revenue was about $77.5 million, up about 22%, led by MACI.

Nitish Kishor | 28 October 2026

Achieve Life Sciences (NASDAQ:ACHV) Slips 3% Premarket Ahead of Planned Fourth-Quarter NDA Resubmission

Achieve Life Sciences (NASDAQ:ACHV) shares are indicated down 3.03% at $6.72 in premarket, after rising 5.96% to close at $6.93 on Tuesday. No company-specific catalyst was identified for the dip, and the healthcare sector ETF is also softer, down about 0.8%, as investors weigh …

Nitish Kishor | 28 October 2026

Axogen (NASDAQ:AXGN) Jumps 20% Premarket on Q3 Beat, Raised Guidance and Prostate Market Plans

Axogen (NASDAQ:AXGN) shares are indicated up 19.83% at $44.89 in premarket after third-quarter results topped expectations and management raised its 2026 outlook. Revenue of $75.8 million, up 26.2% from $60.1 million, beat the roughly $73.2 million consensus, and adjusted EPS of $0.21 beat the …

Nitish Kishor | 28 October 2026

Boston Scientific (NYSE:BSX) Sinks 6% Premarket as Lowered 2026 Outlook Overshadows In-Line Q3

Boston Scientific (NYSE:BSX) shares are indicated down 6.08% at $42.32 in premarket after third-quarter results that were roughly in line but a cut to the 2026 outlook as the August cyberattack weighs on the business. Revenue of $5.14 billion was up 1.5%, and adjusted …

Nitish Kishor | 28 October 2026

Penny Stock Cardiff Oncology (NASDAQ:CRDF) Edges Up 2% Premarket as Leila Alland Joins as Interim Chief Medical Officer

Cardiff Oncology (NASDAQ:CRDF) shares are indicated up 2.23% at $0.89 in premarket after the company appointed Leila Alland, MD, as interim Chief Medical Officer. She succeeds Roger Sidhu, MD, who stepped down. The stock closed Tuesday up 8.80% at $0.88.

Nitish Kishor | 28 October 2026

Penny Stock Cellectis (NASDAQ:CLLS) Rises 6% Premarket on Preclinical Data Showing 70% APOC3 Editing

Cellectis (NASDAQ:CLLS) shares are indicated up 5.71% at $1.11 in premarket after the company presented expanded preclinical data for .HEAL-101, its in vivo base editing candidate targeting APOC3 for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress. The stock closed …

Nitish Kishor | 28 October 2026

Dyne Therapeutics (NASDAQ:DYN) Slips 4% Premarket as Oppenheimer Downgrade Cuts Target to $15

Dyne Therapeutics (NASDAQ:DYN) shares are indicated down 4.19% at $16.23 in premarket after Oppenheimer downgraded the stock to Perform from Outperform and cut its price target to $15 from $40. Uncertainty around vHOT is the main focus for investors, even though the stock jumped …

Nitish Kishor | 28 October 2026
Support

Hi! How can we help you today?

Loading…